{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:11:25Z","timestamp":1780672285402,"version":"3.54.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1053\/j.ajkd.2023.07.009","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T20:44:06Z","timestamp":1693428246000},"page":"116-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Reply to Best Practice for Induction of Immunosuppression in Patients Treated With Daratumumab Is to Be Determined"],"prefix":"10.1053","volume":"83","author":[{"given":"Jennifer S.","family":"Byrns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"Sanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2023.07.009_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/j.ajkd.2023.05.008","article-title":"Best practice for induction of immunosuppression in patients treated with daratumumab is to be determined","volume":"83","author":"Amer","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2023.07.009_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD381 immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"28","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.ajkd.2023.07.009_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"issue":"19","key":"10.1053\/j.ajkd.2023.07.009_bib4","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2023.07.009_bib5","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2023.07.009_bib6","doi-asserted-by":"crossref","first-page":"ofac574","DOI":"10.1093\/ofid\/ofac574","article-title":"Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-cd38 monoclonal antibody-based regimens: a systemic review and meta-analysis","volume":"9","author":"Vassilopoulos","year":"2022","journal-title":"Open Forum Infect Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623007710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623007710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:35:38Z","timestamp":1780670138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638623007710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0272638623007710"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.07.009","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Reply to Best Practice for Induction of Immunosuppression in Patients Treated With Daratumumab Is to Be Determined","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.05.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the","name":"copyright","label":"Copyright"}]}}